Drug Trial Radar · NCT04440735
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Oct 7, 2020
Primary completion
Sep 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Kahr MedicalIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Colorectal Cancer
Interventions
DSP107Biological
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
AtezolizumabBiological
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: Duration of the study, estimated to be 9 months
- Dose Limiting Toxicities (DLT)Time frame: At the end of Treatment Cycle 1 (each cycle is 21 days)
- DSP107 Serum ConcentrationTime frame: At the end of Treatment Cycle 8 (each cycle is 21 days)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Moores Cancer Center, UCSD
La Jolla, California
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)
Aurora, Colorado
Florida Cancer Specialists
Lake Mary, Florida
Indiana University Simon Cancer Center
Indianapolis, Indiana
KUCC / KUMCRI University of Kansas Cancer Center
Kansas City, Kansas
SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center University of Pittsburgh
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.